Paul B. Chapman

Memorial Sloan Kettering Cancer Center — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

74h-index43.5kcitations513works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(252), Cutaneous Melanoma Detection and Management(135), Immunotherapy and Immune Responses(96), CAR-T cell therapy research(95), Cancer Immunotherapy and Biomarkers(89)

Publications512 total

Changing Role of Adjuvant Therapy in Stage III Melanoma
New England Journal of Medicine·2025
Integrated UPper limb and Language Impairment and Functional Training (UPLIFT) after stroke: study protocol for an umbrella Bayesian Optimal Phase IIa clinical trial
BMJ Neurology Open·2025Open Access
Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study
Melanoma Research·2025· 1 citedOpen Access
Chemotherapy-Based Treatment Of Metastatic Melanoma
2024
Melanoma-Specific Targeted Therapies
2024
A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors
Radiotherapy and Oncology·2024· 5 citedOpen Access
Data from Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study
2024Open Access
Data from Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study
2024Open Access
Supplementary Figures 1 from Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study
2024Open Access
Supplementary Tables 1 from Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study
2024Open Access
Supplementary Tables 1 from Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study
2024Open Access
Supplementary Figures 1 from Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study
2024Open Access
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study
Clinical Cancer Research·2024· 7 citedOpen Access
A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease
The Cancer Journal·2024
Supplementary Figure 3 from Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib
2023Open Access
FIGURE 3 from Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib
2023Open Access
TABLE 2 from Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib
2023Open Access
FIGURE 1 from Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib
2023Open Access
TABLE 1 from Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib
2023Open Access
FIGURE 3 from Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib
2023Open Access
page 1 of 26Next →

Frequent Co-authors

Jedd D. Wolchok(16), Keith T. Flaherty(14), Antoni Ribas(13), Katherine S. Panageas(13), Jeffrey A. Sosman(12), Grant A. McArthur(9), Margaret K. Callahan(9), Michael A. Postow(8), Richard D. Carvajal(8), John M. Kirkwood(7), K. B. Nolop(7), David B. Solit(7), Axel Hauschild(6), Caroline Robert(6), Igor Puzanov(6), Neal Rosen(6), Gary K. Schwartz(6), Paolo A. Ascierto(5), Reinhard Dummer(5), Richard J. Lee(5)